Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tercica’s False Advertising Suit Against Insmed Is Dismissed In California

This article was originally published in The Pink Sheet Daily

Executive Summary

San Francisco federal court finds that Insmed's statements to investors about the safety profile of Tercica's growth hormone Increlex do not constitute false advertising.

You may also be interested in...



Insmed, Tercica Head To Court Over Growth Hormone Patents

A San Francisco federal court denied four of Insmed’s five motions for summary judgment, sending the dispute over iPlex and Increlex to trial in November.

Insmed, Tercica Head To Court Over Growth Hormone Patents

A San Francisco federal court denied four of Insmed’s five motions for summary judgment, sending the dispute over iPlex and Increlex to trial in November.

Insmed Growth Treatment iPlex Enters Market

Mecasermin rinfabate injection will compete with Tercica’s Increlex.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS064318

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel